Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis

Potentially eligible participants will be scheduled for an eligibility screening session,
followed by an extensive baseline phenotyping session, which together are expected to take
approximately 2.5 hours to complete. Participants will be provided with breaks as needed
during the clinic visit. The eligibility screening session is intended to collect the
minimally sufficient data to confirm eligibility, so that the extensive baseline phenotyping
session is initiated only for participants highly likely to be confirmed after the 48 hour
urine culture results are known.

Participants who enroll in the study and complete a baseline clinic visit will be followed
up with bi-weekly and bi-monthly internet-based questionnaires, as well as in-clinic visits
at 6 and 12 months.

Participants will provide self-reported symptom data using web based internet tools on a
bi-weekly basis. These questions are expected to be completed within 5-7 minutes.

A more extensive set of questionnaires will be administered to each participant every two
months during the 12-month study period. The bi-monthly assessment will also be administered
via the internet, and the questions are expected to be completed within 10-15 minutes.

Inclusion Criteria:

Participants are eligible for the Trans-MAPP EP if they meet the following:

1. Participant has signed and dated the appropriate Informed Consent document.

2. Agreed to participate in Trans-MAPP EP Study procedures.

3. Participant reports a response of at least 1 on the pain, pressure or discomfort
scale.

For males or females (IC/PBS criteria)

1. Participant reports an unpleasant sensation of pain, pressure or discomfort, perceived
to be related to the bladder and/or pelvic region, associated with lower urinary tract
symptoms for the majority of the time during any 3 months in the previous 6 months or for
the majority of the time during the most recent 3 months.

For males only (CP/CPPS criteria)

1. Male participant reports pain or discomfort in any of the 8 domains of the Male
Genitourinary Pain Index for the majority of the time during any 3 months in the previous
6 months

Exclusion Criteria:

Individuals will not be eligible for enrollment in the Trans-MAPP EP Study if they meet
any of the criteria listed below. Participants who develop any of these exclusion criteria
during the follow-up phase of the study will continue to be followed, and included in the
cohort study.

1. Participant has an on-going symptomatic urethral stricture.

2. Participant has an on-going neurological disease or disorder affecting the bladder or
bowel fistula.

3. Participant has a history of cystitis caused by tuberculosis, radiation therapy or
Cytoxan/cyclophosphamide therapy.

4. Participant has augmentation cystoplasty or cystectomy.

5. Participant has a systemic autoimmune disorder (such as Crohn's Disease or Ulcerative
Colitis, Lupus, Rheumatoid Arthritis, or Multiple Sclerosis).

6. Participant has a history of cancer (with the exception of skin cancer).

7. Participant has current major psychiatric disorder or other psychiatric or medical
issues that would interfere with study participation (e.g. dementia, psychosis,
upcoming major surgery, etc).

8. Participant has severe cardiac, pulmonary, renal, or hepatic disease that in the
judgment of the study physician would preclude participation in this study.

Exclusion Criteria for Males Only

1. Male Participant diagnosed with unilateral orchalgia, without pelvic symptoms.

2. Male Participant has a history of transurethral microwave thermotherapy (TUMT),
transurethral needle ablation (TUNA), balloon dilation, prostate cryo-surgery, or
laser procedure.

Exclusion Criteria for Females Only

1. Female Participant has a history of High-Grade Squamous Intraepithelial Lesion (HGSIL)
/ high-grade cervical dysplasia.